Pharmaceutical sales: 85%
Dermatology sales: 70%
Top 3 markets: Spain (30%), Germany (25%), USA (20%)

Almirall, S.A. generates the majority of its sales from the pharmaceutical sector, with a strong focus on dermatological products. This is reflected in the high percentage distribution of sales within dermatology.

The key markets for Almirall are Spain, Germany, and the USA. Spain remains the largest market, accounting for 30% of total sales, followed by Germany at 25% and the USA at 20%. These markets are crucial for the company as they are the main sources of revenue and growth.

Production sites of Almirall, S.A.:

1. Spain: Main production facilities are located in Sant Andreu de la Barca and Sant Celoni.
2. Germany: Production site in Reinbek.

Almirall, S.A. is a leading pharmaceutical company headquartered in Barcelona, Spain. The production sites in Spain and Germany are strategically positioned to efficiently serve the European markets. These locations specialize in the manufacturing of pharmaceutical products used in the fields of dermatology, neurology, and other therapeutic areas.

Focus on Dermatology: Almirall has strategically focused on the field of dermatology to drive its growth.

Investments in Research and Development: The company continuously invests in R&D to develop innovative dermatological products.

Strategic Partnerships: Almirall enters targeted partnerships and alliances to strengthen its product pipeline and tap into new markets.

Almirall, S.A. pursues a clear growth strategy that focuses on strengthening its position in the field of dermatology. Through significant investments in research and development, the company aims to bring innovative solutions to the market that meet the needs of patients.

In addition, Almirall relies on strategic partnerships and alliances to expand its product pipeline and increase its geographical reach. This strategy is intended to enable the company to succeed in both existing and new markets.

Main raw materials: Pharmaceutical active ingredients, excipients, packaging materials
Countries of origin: China, India, Germany, USA

Almirall, S.A. is a pharmaceutical company that imports a variety of raw materials for the production of its products. The main raw materials include pharmaceutical active ingredients (APIs), which are essential for the production of medications. These are often sourced from countries such as China and India, which are leading producers of APIs worldwide.

In addition, Almirall imports excipients that contribute to the stability and efficacy of the medications, as well as packaging materials necessary for the distribution and storage of the products. Germany and the USA are also important partners, especially for high-quality pharmaceutical products and technologies.

The exact composition and origin of the raw materials may vary depending on the product line, with Almirall striving to source high-quality materials from reliable sources to ensure the safety and efficacy of their products.

Market Share in Dermatology: 12% (estimated 2026)
R&D Investments: 18% of revenue (2025)
EBITDA Margin: 25% (2025)

Almirall, S.A. has established itself as a significant player in the field of dermatology, with an estimated market share of 12% in 2026. The company's competitive advantage lies primarily in its strong focus on research and development, investing about 18% of its revenue in this area. These investments enable Almirall to develop innovative products and differentiate itself from the competition.

Furthermore, the EBITDA margin of 25% in 2025 shows that the company operates efficiently and is able to manage its cost structure well. This financial health gives Almirall the flexibility to continue investing in growth and innovation.

In addition, Almirall benefits from strategic partnerships and alliances that strengthen its product pipeline and facilitate access to new markets. In a competitive environment, this combination of innovation, efficiency, and strategic alliances is a key competitive advantage.

Institutional Investor Share: approximately 50% (estimated, 2026)

Insider Buys/Sells: No significant transactions in the last year (estimated, 2026)

The institutional investor share at Almirall, S.A. is estimated to be around 50%. This is typical for larger publicly traded companies, as institutional investors such as pension funds, investment funds, and insurance companies often hold significant stakes.

In 2026, there were no significant insider transactions that could indicate a change in management's confidence in the company's future development. This suggests that the management has a stable outlook on the company's development.

Market share of Almirall, S.A.: 3.5% (estimated, 2026)

Top competitors and their market shares:

1. Novartis AG: 12.0%
2. Sanofi S.A.: 11.5%
3. GlaxoSmithKline plc: 10.8%
4. Pfizer Inc.: 9.7%
5. Roche Holding AG: 8.9%
6. Merck & Co., Inc.: 8.2%
7. AstraZeneca plc: 7.5%
8. Bayer AG: 6.8%
9. AbbVie Inc.: 5.9%
10. Almirall, S.A.: 3.5%

Almirall, S.A. is a specialized player in the field of dermatology and has focused on niche products, giving it a certain moat in this segment. The focus on innovative dermatological solutions and the development of new therapies provide Almirall with an advantage in this specialized area.

However, compared to large pharmaceutical companies with a broader product portfolio and more extensive resources, Almirall's moat is less pronounced. Companies like Novartis and Sanofi have strong research and development departments and a global presence that give them a significant advantage.

Almirall's advantage lies in its specialization and ability to quickly respond to market changes in dermatology. Nevertheless, competition remains intense, and larger competitors tend to have stronger moats due to their more comprehensive resources and wider product ranges.

Revenue Growth: 8% (2025) Research and Development Ratio: 15% of revenue (2025) Net Income Growth: 10% (2025)

Almirall, S.A. has experienced solid revenue growth of 8% in recent years, attributed to a successful product pipeline and a strong market position in dermatology. The company continues to heavily invest in research and development, accounting for 15% of revenue. This indicates that Almirall is committed to expanding its product range and bringing innovative solutions to the market.

The 10% net income growth in 2025 shows that the company is operating profitably and has been able to increase its efficiency. These metrics suggest that Almirall is well positioned to benefit from future market developments.

However, investors should also consider the overall market conditions and potential risks, such as regulatory changes or market volatility. Overall, Almirall appears to be a promising investment, especially for investors interested in long-term growth.

Dividend yield: 3.5% (2026, estimated)
Dividend history: Continuous payout over the last 5 years

Almirall, S.A. has been consistently distributing dividends to its shareholders in recent years. The dividend yield is currently around 3.5%, which can be considered moderate compared to other companies in the pharmaceutical industry.

The company has pursued a solid dividend policy, with payouts being made regularly over the past five years. This indicates a certain level of reliability, although future payouts could depend on overall business performance and market conditions. Analysts view Almirall's dividend policy as stable as long as the company maintains its financial health.